Roy Herbst, MD, PhDEnriched profile
Deputy Director, Yale Cancer Center; Chief of Medical Oncology and Hematology, Yale Cancer Center and Smilow Cancer Hospital; Ensign Professor of Medicine (Medical Oncology) and Professor of Pharmacology, Yale School of Medicine (through mid-July 2026; named Director of Dartmouth Cancer Center, effective July 13, 2026) · Yale Cancer Center
Overview
Updated 14 Jul 2026
Roy S. Herbst is Deputy Director, Yale Cancer Center at Yale School of Medicine / Yale Cancer Center (transitioning to Dartmouth Cancer Center as Director effective July 13, 2026). The public record shows 1,336 publications with 94,089 citations (h-index 135), centered on Lung Cancer Treatments and Mutations, Cancer Immunotherapy and Biomarkers, Lung Cancer Research Studies. It also documents an investigator role on 8 registered clinical trials, 2 NIH-funded awards (2001–2010).
- Most recent indexed publication: 2026 · Cancer discovery
- Top research focus: Lung Cancer Treatments and Mutations
- 8 registered trials on ClinicalTrials.gov
Generated from the cited public record · current as of 14 Jul 2026. Every fact links its source below.
Indications focusfrom trials led + research topics
Research focusOpenAlex concept fingerprint
Drugs & moleculesacross trials, industry payments and publications
Works withtrial sponsors and companies reporting payments
Scholarshipindexed output and impact (OpenAlex)
View publications ↓Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 487.
Clinical & industrytrials, payments and federal funding
Not shown. No U.S. clinical registration on file.
Public positionssourced statements on record
- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →medicine.yale.edu ↗
- Chair
AACR Science Policy and Government Affairs Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
This is a research profile, built on the published record. There's no U.S. clinical registration (NPI) on file, so facts that hang off one (clinical specialty, industry payments) aren't shown. We'd rather leave a gap than guess. Why? →
Clinical trials
Updated 14 Jul 2026
Listed as an investigator on 8 registered studies on ClinicalTrials.gov. The most recent:
- S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
Sponsor: SWOG Cancer Research Network
InvestigatorPhase 3TerminatedNCT00946712 - PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
Sponsor: M.D. Anderson Cancer Center
InvestigatorPhase 2CompletedNCT00276523 - S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer
Sponsor: SWOG Cancer Research Network
InvestigatorPhase 2CompletedNCT00085501
Industry payments
Not shown. This person has no U.S. clinical registration (NPI) on file, so we can't reliably tie industry payments reported to CMS to them. We'd rather leave a gap than guess. Why? →
NIH funding
Updated 14 Jul 2026
2 NIH research awards on record, funded 2001–2010 per NIH RePORTER. The latest:
- Yale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung Cancer
Yale University
FY2025$2,341,652P50CA196530 - Yale Cancer Center Advanced Training Program for Physician-Scientists (YCC-ATPP)
Yale University
FY2025$510,054T32CA233414
Publications
Updated 14 Jul 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma.
Nature communications
2025 - The evolving immuno-angiogenic paradigm in NSCLC: lessons from ivonescimab.
Nature reviews. Clinical oncology
2025
Most-cited worksby citation count (OpenAlex)
- 01
- 02
- 03The biology and management of non-small cell lung cancer4,963 citations2018
- 04
- 05Lung Cancer2,392 citations2008
Contact
An office address from a public listing. This research profile has no federal registry record to draw from.
Office address
Smilow Cancer Hospital, 35 Park St, New Haven, CT 06519
Network
Updated 14 Jul 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Background & recognition
Updated 14 Jul 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Educationdegrees and training on record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- Board Certified
Medical Oncology (American Board of Internal Medicine)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →healthgrades.com ↗
Editorial & leadership rolesjournal and society appointments
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Awards & honorshonors on the public record
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Secondary affiliationsappointments beyond the home institution
- Assistant Dean
Office of the Dean, Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Program Director
Master of Health Science - Clinical Investigation Program (MHS-CI), Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗ - Secondary appointment
Department of Pharmacology, Yale School of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →medicine.yale.edu ↗
Media & interviewspress, podcasts and appearances
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →yalemedicine.org ↗
- Interview
"Making a Mark in Lung Cancer: An Interview With Roy S. Herbst, MD, PhD," OncLive/Oncology Live
2011verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →onclive.com ↗ - Listed expert commentator
Yale Office of Public Affairs & Communications media experts directory
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →communications.yale.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Online presence
Updated 14 Jul 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accountspublic accounts run by this person
- LinkedIn
linkedin.com/in/roy-herbst-16b260106
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - Google Scholar
scholar.google.com/citations
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →scholar.google.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Roy-S-Herbst-38649626
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗
Mentions by otherswhere others cite or feature them
- Facebook
facebook.com/SmilowCancerHospital/posts/dr-roy-herbst-deputy-director-of-yale-cancer-center-and-chief-of-medical-oncolog/6486531174725448
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →facebook.com ↗ - Instagram
instagram.com/p/C4WkX7AM_Tw
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →instagram.com ↗ - ResearchGate
researchgate.net/scientific-contributions/Roy-Herbst-2179118794
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →researchgate.net ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Eric Winer, MD
Yale Cancer Center
- 1,624
- publications
- 171
- h-index
- 20
- trials
Charles Fuchs, MD, MPH
Yale Cancer Center
- 1,721
- publications
- 172
- h-index
- 7
- trials
Mario Sznol, MD
Yale Cancer Center
- 536
- publications
- 92
- h-index
- 18
- trials
Patricia Lorusso, DO
Yale Cancer Center
- 1,281
- publications
- 86
- h-index
- 31
- trials